论文部分内容阅读
目的:评价奥曲肽对消化道恶性肿瘤患者血清中血管内皮生长因子(VEGF)、胰岛素样生长因子1(IGF- 1)的影响。方法:奥曲肽0 2mg皮下注射, q12h连用7天,治疗经病理组织学或细胞学检查证实的消化道恶性肿瘤患者13例,采用人VEGF、IGF-1定量EIA试剂盒统一测定治疗前后血清中VEGF、IGF 1的含量。结果:VEGF明显下降5例(38.5% ),全组治疗前均值为187.18pg/ml,治疗后均值为87.18pg/ml;IGF 1明显下降6例(46.2% ),全组治疗前均值为36 65ng/ml,治疗后均值为24 52ng/ml。结论:生长抑素类似物奥曲肽能明显降低消化道肿瘤患者血清中VEGF、IGF 1的水平。
Objective: To evaluate the effect of octreotide on serum vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1) in patients with gastrointestinal cancer. Methods: Octreotide 0 2mg was injected subcutaneously for q12h for 7 days. Thirteen patients with malignant tumors of the digestive tract confirmed by histopathology and cytology were treated with human VEGF and IGF-1 quantitative EIA kit for determination of serum VEGF , IGF 1 content. Results: VEGF was significantly decreased in 5 cases (38.5%), the average before treatment was 187.18pg / ml, the average after treatment was 87.18pg / ml; IGF 1 decreased significantly in 6 cases (46.2%), 65ng / ml, after treatment mean 2452ng / ml. Conclusion: The somatostatin analogue octreotide can significantly reduce the serum levels of VEGF and IGF-1 in patients with gastrointestinal cancer.